Lyell Immunopharma Inc (LYEL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -274,448 | -342,994 | -234,632 | -183,118 | -250,219 |
| Depreciation Amortization | 6,580 | 4,950 | 10,654 | 17,090 | 15,525 |
| Accounts payable and accrued liabilities | -2,339 | -3,234 | 1,464 | 667 | 91 |
| Other Working Capital | -9,894 | -3,120 | 3,421 | -82,015 | 4,015 |
| Other Operating Activity | 130,077 | 182,004 | 55,399 | 77,821 | 104,339 |
| Operating Cash Flow | $-150,024 | $-162,394 | $-163,694 | $-169,555 | $-126,249 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 95,785 | 154,234 | 186,734 | 12,736 | -56,069 |
| PPE Investments | -41,688 | -31,810 | -2,686 | -24,276 | -65,504 |
| Investing Cash Flow | $54,097 | $122,424 | $184,048 | $-11,540 | $-121,573 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 50,000 | N/A | N/A | N/A | N/A |
| Common Stock Issued | 407 | 1,402 | 2,200 | 11,096 | 401,244 |
| Other Financing Activity | -1 | -76 | -457 | -461 | 0 |
| Financing Cash Flow | $50,406 | $1,326 | $1,743 | $10,635 | $401,244 |
| Beginning Cash Position | 107,287 | 145,931 | 123,834 | 294,294 | 140,872 |
| End Cash Position | 61,766 | 107,287 | 145,931 | 123,834 | 294,294 |
| Net Cash Flow | $-45,521 | $-38,644 | $22,097 | $-170,460 | $153,422 |
| Free Cash Flow | |||||
| Operating Cash Flow | -150,024 | -162,394 | -163,694 | -169,555 | -126,249 |
| Capital Expenditure | -41,975 | -31,810 | -2,686 | -24,276 | -65,504 |
| Free Cash Flow | -191,999 | -194,204 | -166,380 | -193,831 | -191,753 |